The Francis Crick Institute
1-s2.0-S2451945619300832-main.pdf (2.5 MB)

Validation and invalidation of chemical probes for the human N-myristoyltransferases.

Download (2.5 MB)
journal contribution
posted on 2020-01-06, 17:42 authored by Wouter W Kallemeijn, Gregor A Lueg, Monica Faronato, Kate Hadavizadeh, Andrea Goya Grocin, Ok-Ryul Song, Michael Howell, Dinis P Calado, Edward W Tate
On-target, cell-active chemical probes are of fundamental importance in chemical and cell biology, whereas poorly characterized probes often lead to invalid conclusions. Human N-myristoyltransferase (NMT) has attracted increasing interest as target in cancer and infectious diseases. Here we report an in-depth comparison of five compounds widely applied as human NMT inhibitors, using a combination of quantitative whole-proteome N-myristoylation profiling, biochemical enzyme assays, cytotoxicity, in-cell protein synthesis, and cell-cycle assays. We find that N-myristoylation is unaffected by 2-hydroxymyristic acid (100 μM), D-NMAPPD (30 μM), or Tris-DBA palladium (10 μM), with the latter compounds causing cytotoxicity through mechanisms unrelated to NMT. In contrast, drug-like inhibitors IMP-366 (DDD85646) and IMP-1088 delivered complete and specific inhibition of N-myristoylation in a range of cell lines at 1 μM and 100 nM, respectively. This study enables the selection of appropriate on-target probes for future studies and suggests the need for reassessment of previous studies that used off-target compounds.


Crick (Grant ID: 10057, Grant title: Calado FC001057) Medical Research Council (Grant ID: MR/J008060/1, Grant title: MRC MR/J008060/1)